CIRC launches advanced 13C breath analyzer for gastric cancer screening

China Isotope & Radiation Corporation (CIRC) has announced the launch of its novel Su π one 13C breath analyzer, following successful obtainment of a Class II medical device registration certificate. This independently developed device represents a significant advancement in Helicobacter pylori breath testing technology, offering a more reliable, efficient, and convenient solution for diagnosis.

The Su π one 13C breath analyzer boasts high efficiency, reducing testing time for a set of samples from a minimum of 2 minutes to just 30 seconds. This improvement enhances user experience, and its higher testing accuracy enables adaptation to a broader range of large-scale Helicobacter pylori screening scenarios. The device is expected to boost healthcare resource utilization and provide crucial technological support for establishing early screening, diagnosis prevention, and control systems for gastric cancer in China.

As of September 8, 2025, the board of directors comprises Xiao Yafei, Zhang Junqi, Huo Yingying, and Ma Xiaoyu as executive directors; Chen Zan, Ding Jianmin, and Chang Jinyu as non-executive directors; and Poon Chiu Kwok, Chen Jingshan, Lu Chuang, and An Rui as independent non-executive directors, with Xiao Yafei serving as chairman.